About astria therapeutics inc - ATXS
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
ATXS At a Glance
Astria Therapeutics, Inc.
22 Boston Wharf Road
Boston, Massachusetts 02210
| Phone | 1-617-349-1971 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -94,260,000.00 | |
| Sector | Health Technology | Employees | 78 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ATXS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.253 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.462 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.019 |
ATXS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,208,461.538 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ATXS Liquidity
| Current Ratio | 17.492 |
| Quick Ratio | 17.492 |
| Cash Ratio | 17.152 |
ATXS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -31.576 |
| Return on Equity | -33.522 |
| Return on Total Capital | -29.037 |
| Return on Invested Capital | -33.287 |
ATXS Capital Structure
| Total Debt to Total Equity | 1.677 |
| Total Debt to Total Capital | 1.649 |
| Total Debt to Total Assets | 1.564 |
| Long-Term Debt to Equity | 1.772 |
| Long-Term Debt to Total Capital | 1.223 |